Erlotinib Hydrochloride - Uses, Dosage, Side Effects, Interaction

Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury.

Erlotinib is a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Erlotinib is a quinazoline compound having a (3-ethynyl phenyl)amino group at the 4-position and two 2-methoxy ethoxy groups at the 6- and 7-positions. It has a role as an antineoplastic agent, a protein kinase inhibitor, and an epidermal growth factor receptor antagonist. It is a member of quinazolines, a terminal acetylenic compound, an aromatic ether, and a secondary amino compound.

Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer, and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders

Mechanism of Action

The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). The specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.

Although the exact mechanism of antineoplastic activity of erlotinib has not been fully elucidated, erlotinib appears to inhibit the intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on the surface of normal and cancer cells. Specificity with regard to other tyrosine kinase receptors has not been fully characterized.

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong survival after the failure of first-line or second-line chemotherapy. However, little is known about its effects on the immune system. In the present study, /investigators/ aimed to investigate the immunosuppressive activity of erlotinib on T lymphocytes both in vitro and in vivo, and further explore its potential molecular mechanism. Erlotinib exerted a significant inhibition on the T cell proliferation and activation induced by concanavalin A, anti-CD3 plus anti-CD28, staphylococcal enterotoxin B or phorbol myristate acetate respectively in a concentration-dependent manner and also inhibited the secretion of the proinflammatory cytokines such as IL-2 and IFN-gamma of activated T cells. Further study showed that erlotinib caused G0/G1 arrest and suppressed the phosphorylations of c-Raf, ERK, and Akt in activated T cells. Moreover, erlotinib significantly ameliorated picryl chloride-induced ear contact dermatitis in a dose-dependent manner in vivo. In summary, these findings suggest that erlotinib may cause the impairment of T-cell-mediated immune response both in vitro and in vivo through inhibiting T-cell proliferation and activation, which is closely associated with its potent down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.

Indications

Erlotinib is indicated for: – The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. – In combination with the first-line treatment for patients diagnosed with locally advanced, unresectable, or metastatic pancreatic cancer. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally, it is not recommended for use in combination with platinum-based chemotherapy.
Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth
Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer.
Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC – negative tumors.
Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib hydrochloride in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.
Locally Advanced Pancreatic Cancer (LAPC)
Metastatic Non-Small Cell Lung Cancer
Pancreatic Metastatic Cancer
Unresectable Pancreatic Cancer

Use in Cancer

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

Non-small cell lung cancer (NSCLC) is metastatic and has certain EGFR gene mutations. It may be used:
- As the first therapy.
- In patients on maintenance therapy or whose disease has gotten worse after treatment with chemotherapy.
The use of erlotinib hydrochloride to treat NSCLC that does not have the EGFR gene mutations is no longer FDA-approved.
Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose cancer cannot be removed by surgery or has spread.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.

Contraindications

Interstitial lung disease (ILD) Severe hepatic toxicity that is unimproved or does not resolve.
GI perforation.
Severe bullous, blistering, or exfoliating skin conditions.
Corneal perforation or severe ulceration.
liver cancer
dehydration
low amount of potassium in the blood
a type of blood disorder where the red blood cells burst called hemolytic anemia
increased risk of bleeding due to clotting disorder
decreased blood platelets
an ulcer of the cornea of the eye
a heart attack
a low supply of oxygen-rich blood to the heart
thrombotic thrombocytopenic purpura, a type of blood disorder
bleeding
a type of inflammation of the lung called interstitial pneumonitis
a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis
acute respiratory distress syndrome, a type of lung disorder
liver problems
acute renal failure in patients with serious liver disease
the high amount of bilirubin in the blood
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding
a rupture in the wall of the stomach or intestine
tobacco smoking
lung tissue problem
kidney disease with likely reduction in kidney function

Dosage

Strengths: 25 mg; 100 mg; 150 mg

Non-Small Cell Lung Cancer

150 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food)
Duration of therapy: Until disease progression or unacceptable toxicity

Pancreatic Cancer

100 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food)
Duration of therapy: Until disease progression or unacceptable toxicity

Therapy should be interrupted or discontinued if:

Total serum bilirubin doubles and/or serum transaminases triple in patients with baseline hepatic impairment
Total serum bilirubin is greater than 3 times the upper limit of normal (3 x ULN) and/or serum transaminases are greater than 5 x ULN in patients with normal pretreatment values.

Dose Adjustments

Discontinue therapy for:

Interstitial Lung Disease (ILD)
Severe hepatic toxicity that does not improve significantly or resolve within 3 weeks
GI perforation
Severe bullous, blistering, or exfoliating skin conditions
Corneal perforation or severe ulceration

Interrupt therapy:

During diagnostic evaluation for ILD
In patients with preexisting hepatic impairment or biliary obstruction for doubling of bilirubin or tripling of transaminases values over baseline; consider discontinuing therapy
In patients without preexisting hepatic impairment for total bilirubin levels greater than 3 x ULN or transaminases greater than 5 x ULN; consider discontinuing therapy
For severe (CTCAE grade 3 to 4) renal toxicity; consider discontinuing therapy
For persistent severe diarrhea not responsive to medical management (e.g., loperamide)
For severe rash not responsive to medical management
For Grade 3 or 4 keratitis or Grade 2 keratitis lasting more than 2 weeks
For acute/worsening ocular disorders such as eye pain; consider discontinuing therapy
If severe reactions occur with concomitant use of strong CYP450 3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole), or grapefruit or grapefruit juice, or when used concomitantly with an inhibitor of both CYP450 3A4 and CYP450 1A2 (e.g., ciprofloxacin): Reduce dose by 50 mg decrements and avoid concomitant use if possible
Concomitant use with CYP450 3A4 inducers (e.g., rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St. John’s Wort: Increase dose by 50 mg increments every 2 weeks to a maximum dose of 450 mg as tolerated; avoid concomitant use if possible
Concurrent cigarette smoking: Increase the dose by 50 mg every 2 weeks to a maximum dose of 300 mg. Upon cessation of smoking, immediately reduce the dose to the recommended dose (150 mg or 100 mg daily)
Proton pump inhibitors: Avoid concomitant use if possible; separation of doses may not eliminate the interaction since proton pump inhibitors affect the pH of the upper GI tract for an extended period
H2-receptor antagonists: Erlotinib must be taken 10 hours after the H2-receptor antagonist and at least 2 hours before the next dose of the H2-receptor antagonist
Antacids: The antacid dose and the dose of erlotinib should be separated by several hours if an antacid is necessary; the effect of antacids on erlotinib pharmacokinetics has not been evaluated

Administration advice:

Take this drug at least 1 hour before or 2 hours after food.
Avoid taking this drug with antacids, histamine-2 antagonists, and proton pump inhibitors.

Side Effects

The Most Common

diarrhea
loss of appetite
nausea
vomiting
heartburn
gas
constipation
mouth sores
weight loss
extreme tiredness
headache
bone or muscle pain
depression
anxiety
numbness, burning, or tingling of the hands or feet
swelling of the arms, hands, feet, ankles, or lower legs
darkening of skin
hair loss
changes in the appearance of the hair and nails
rash (may look like acne and may affect the skin on the face, upper chest, or back)
blistering, peeling, dry, or cracked skin
itching, tenderness, or burning of the skin
shortness of breath
cough
fever or chills
growth of eyelashes on the inside of the eyelid
severe stomach pain
dry, red, painful, teary, or irritated eyes
blurred vision
eye sensitivity to light
chest pain or pressure
pain in the arms, neck, or upper back
rapid, irregular, or pounding heartbeat
slow or difficult speech
dizziness or faintness
weakness or numbness of an arm or leg
unusual bruising or bleeding
black and tarry or bloody stools
vomit that is bloody or looks like coffee grounds
sunken eyes
dry mouth
decreased urination
dark urine
pale or yellow skin
redness, warmth, pain, tenderness, or swelling in one leg

More common

Burning, tingling, numbness or pain in the hands, arms, feet, or legs
cough or hoarseness
diarrhea (severe)
difficult or labored breathing
fever or chills
lower back or side pain
painful or difficult urination
rash (severe)
sensation of pins and needles
stabbing chest pain
tightness in the chest
Acid or sour stomach
belching
blemishes on the skin
bloated or full feeling
bone pain
burning, dry, or itching eyes
diarrhea (mild)
difficulty with moving
dizziness
dry eyes
dry skin
excess air or gas in the stomach or intestines
excessive tearing

Rare

Bloody or black, tarry stools
blurred vision
chest pain or discomfort
constipation
convulsions (seizures)
eye irritation or redness
inability to speak
pain or discomfort in the arms, jaw, back, or neck
severe stomach pain
slurred speech
sudden, severe chest pain
sudden, severe headache
sudden, severe weakness in the arm or leg on one side of the body
sweating
vision changes
vomiting of blood or material that looks like coffee grounds
Agitation
blistering, peeling, or loosening of the skin
bloody nose
burning feeling in the chest or stomach
burning upper abdominal or stomach pain
confusion
dark-colored urine
darkening of the skin
decreased urine output
general feeling of tiredness or weakness
headache
increased thirst
irregular heartbeat
lethargy
light-colored stools
loss of appetite
mood changes
muscle pain or stiffness
muscle twitching
nausea or vomiting
rapid weight gain
red skin lesions, often with a purple center
sore throat
sores, ulcers, or white spots in the mouth or on the lips
stomach pain, continuing
stupor
swelling of the face, ankles, or hands
tenderness in the stomach area
trouble breathing
unusual tiredness or weakness
yellow eyes or skin

Drug Interaction

DRUG	INTERACTION
Abacavir	The metabolism of Abacavir can be decreased when combined with Erlotinib.
Abaloparatide	The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Erlotinib.
Abametapir	The serum concentration of Erlotinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Erlotinib can be increased when combined with Abatacept.
Abemaciclib	The metabolism of Abemaciclib can be decreased when combined with Erlotinib.
Abiraterone	The serum concentration of Erlotinib can be increased when it is combined with Abiraterone.
Acalabrutinib	The metabolism of Erlotinib can be decreased when combined with Acalabrutinib.
Acebutolol	The metabolism of Erlotinib can be decreased when combined with Acebutolol.
Acenocoumarol	The serum concentration of Acenocoumarol can be increased when it is combined with Erlotinib.
Acetaminophen	The serum concentration of Erlotinib can be decreased when it is combined with Acetaminophen.
Acetazolamide	The metabolism of Erlotinib can be decreased when combined with Acetazolamide.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Erlotinib.
Acyclovir	The metabolism of Acyclovir can be decreased when combined with Erlotinib.
Adalimumab	The metabolism of Erlotinib can be increased when combined with Adalimumab.
Adenosine	The risk or severity of QTc prolongation can be increased when Adenosine is combined with Erlotinib.
Afatinib	Erlotinib may decrease the excretion rate of Afatinib which could result in a higher serum level.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Erlotinib.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Erlotinib.
Albendazole	The metabolism of Erlotinib can be increased when combined with Albendazole.
Aldesleukin	The metabolism of Erlotinib can be decreased when combined with Aldesleukin.
Alectinib	The metabolism of Alectinib can be decreased when combined with Erlotinib.
Alfentanil	The metabolism of Erlotinib can be decreased when combined with Alfentanil.
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Erlotinib.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Erlotinib.
Allopurinol	Erlotinib may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate	Almasilate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almotriptan	The metabolism of Erlotinib can be decreased when combined with Almotriptan.
Alogliptin	The metabolism of Erlotinib can be decreased when combined with Alogliptin.
Alosetron	The metabolism of Erlotinib can be decreased when combined with Alosetron.
Alpelisib	The serum concentration of Erlotinib can be decreased when it is combined with Alpelisib.
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Erlotinib.
Aluminium	Aluminium phosphate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Erlotinib.
Ambrisentan	The metabolism of Erlotinib can be decreased when combined with Ambrisentan.
Amifampridine	The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Erlotinib.
Aminoglutethimide	The serum concentration of Erlotinib can be decreased when it is combined with Aminoglutethimide.
Aminophenazone	The metabolism of Erlotinib can be decreased when combined with Aminophenazone.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Erlotinib.
Amiodarone	The metabolism of Erlotinib can be decreased when combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Erlotinib.
Amitriptyline	The metabolism of Erlotinib can be decreased when combined with Amitriptyline.
Amobarbital	The serum concentration of Erlotinib can be decreased when it is combined with Amobarbital.
Amodiaquine	The metabolism of Erlotinib can be decreased when combined with Amodiaquine.
Amoxapine	The metabolism of Erlotinib can be decreased when combined with Amoxapine.
Amphetamine	The metabolism of Erlotinib can be decreased when combined with Amphetamine.
Amprenavir	The metabolism of Erlotinib can be decreased when combined with Amprenavir.
Anagrelide	The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Erlotinib.
Anakinra	The metabolism of Erlotinib can be increased when combined with Anakinra.
Anastrozole	The metabolism of Erlotinib can be decreased when combined with Anastrozole.
Antazoline	The risk or severity of QTc prolongation can be increased when Antazoline is combined with Erlotinib.
Antipyrine	The metabolism of Erlotinib can be decreased when combined with Antipyrine.
Apalutamide	The metabolism of Erlotinib can be increased when combined with Apalutamide.
Apixaban	The metabolism of Erlotinib can be decreased when combined with Apixaban.
Apomorphine	The metabolism of Erlotinib can be decreased when combined with Apomorphine.
Apremilast	The metabolism of Erlotinib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Erlotinib can be decreased when combined with Aprepitant.
Arformoterol	The metabolism of Erlotinib can be decreased when combined with Arformoterol.
Aripiprazole	The metabolism of Aripiprazole can be decreased when combined with Erlotinib.
Aripiprazole lauroxil	The metabolism of Aripiprazole lauroxil can be decreased when combined with Erlotinib.
Armodafinil	The serum concentration of Erlotinib can be decreased when it is combined with Armodafinil.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Arsenic trioxide.
Artemether	The serum concentration of Erlotinib can be decreased when it is combined with Artemether.
Artenimol	The metabolism of Erlotinib can be decreased when combined with Artenimol.
Articaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Articaine.
Asciminib	The serum concentration of Erlotinib can be increased when it is combined with Asciminib.
Asenapine	Asenapine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Astemizole	The metabolism of Astemizole can be decreased when combined with Erlotinib.
Asunaprevir	The serum concentration of Erlotinib can be decreased when it is combined with Asunaprevir.
Atazanavir	The metabolism of Erlotinib can be decreased when combined with Atazanavir.
Atenolol	The metabolism of Erlotinib can be decreased when combined with Atenolol.
Atomoxetine	The metabolism of Erlotinib can be decreased when combined with Atomoxetine.
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Erlotinib.
Atropine	The risk or severity of QTc prolongation can be increased when Atropine is combined with Erlotinib.
Avacopan	The metabolism of Erlotinib can be decreased when combined with Avacopan.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Erlotinib.
Avatrombopag	The metabolism of Erlotinib can be increased when combined with Avatrombopag.
Axitinib	The metabolism of Axitinib can be decreased when combined with Erlotinib.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Erlotinib.
Azathioprine	The metabolism of Azathioprine can be decreased when combined with Erlotinib.
Azelastine	The metabolism of Erlotinib can be decreased when combined with Azelastine.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Erlotinib.
Bazedoxifene	The metabolism of Bazedoxifene can be decreased when combined with Erlotinib.
Beclomethasone	The serum concentration of Erlotinib can be decreased when it is combined with Beclomethasone dipropionate.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Erlotinib.
Belinostat	The metabolism of Belinostat can be decreased when combined with Erlotinib.
Belzutifan	The serum concentration of Erlotinib can be decreased when it is combined with Belzutifan.
Bendamustine	The metabolism of Bendamustine can be decreased when combined with Erlotinib.
Benzatropine	The metabolism of Erlotinib can be decreased when combined with Benzatropine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Benzocaine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Benzyl alcohol.
Bepridil	The metabolism of Erlotinib can be decreased when combined with Bepridil.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Erlotinib.
Betamethasone	The serum concentration of Erlotinib can be decreased when it is combined with Betamethasone.
Betamethasone	The metabolism of Erlotinib can be increased when combined with Betamethasone phosphate.
Betaxolol	The metabolism of Erlotinib can be decreased when combined with Betaxolol.
Bexarotene	The serum concentration of Erlotinib can be decreased when it is combined with Bexarotene.
Bezafibrate	The metabolism of Erlotinib can be decreased when combined with Bezafibrate.
Bicalutamide	The metabolism of Erlotinib can be decreased when combined with Bicalutamide.
Bictegravir	The metabolism of Bictegravir can be decreased when combined with Erlotinib.

Bifonazole	The metabolism of Erlotinib can be decreased when combined with Bifonazole.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Erlotinib.
Bimekizumab	The metabolism of Erlotinib can be increased when combined with Bimekizumab.
Binimetinib	The metabolism of Binimetinib can be decreased when combined with Erlotinib.
Biperiden	The metabolism of Erlotinib can be decreased when combined with Biperiden.
Bismuth subnitrate	Bismuth subnitrate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boceprevir	The metabolism of Erlotinib can be decreased when combined with Boceprevir.
Bortezomib	The metabolism of Bortezomib can be decreased when combined with Erlotinib.
Bosentan	The serum concentration of Erlotinib can be decreased when it is combined with Bosentan.
Bosutinib	The metabolism of Bosutinib can be decreased when combined with Erlotinib.
Brentuximab	The metabolism of Brentuximab vedotin can be decreased when combined with Erlotinib.
Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Erlotinib.
Brexpiprazole	The metabolism of Erlotinib can be decreased when combined with Brexpiprazole.
Brigatinib	The serum concentration of Erlotinib can be decreased when it is combined with Brigatinib.
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Erlotinib.
Bromotheophylline	The metabolism of Bromotheophylline can be decreased when combined with Erlotinib.
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Erlotinib.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Erlotinib.
Budesonide	The serum concentration of Erlotinib can be decreased when it is combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Bupivacaine.
Buprenorphine	The metabolism of Erlotinib can be decreased when combined with Buprenorphine.
Bupropion	The metabolism of Erlotinib can be decreased when combined with Bupropion.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Erlotinib.
Buspirone	The metabolism of Erlotinib can be decreased when combined with Buspirone.
Busulfan	The metabolism of Busulfan can be decreased when combined with Erlotinib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butacaine.
Butalbital	The serum concentration of Erlotinib can be decreased when it is combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Erlotinib.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Erlotinib.
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Erlotinib.
Cabotegravir	The metabolism of Cabotegravir can be decreased when combined with Erlotinib.
Cabozantinib	The metabolism of Erlotinib can be decreased when combined with Cabozantinib.
Caffeine	The metabolism of Erlotinib can be decreased when combined with Caffeine.
Calcitriol	The serum concentration of Erlotinib can be decreased when it is combined with Calcitriol.
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Canakinumab	The metabolism of Erlotinib can be increased when combined with Canakinumab.
Candesartan	The metabolism of Erlotinib can be decreased when combined with Candesartan cilexetil.
Candicidin	The metabolism of Erlotinib can be decreased when combined with Candicidin.
Cannabidiol	The metabolism of Erlotinib can be decreased when combined with Cannabidiol.
Capecitabine	The serum concentration of Erlotinib can be increased when it is combined with Capecitabine.
Capmatinib	The serum concentration of Erlotinib can be increased when it is combined with Capmatinib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Capsaicin.
Carbamazepine	The metabolism of Erlotinib can be increased when combined with Carbamazepine.
Carbimazole	The therapeutic efficacy of Carbimazole can be decreased when used in combination with Erlotinib.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Erlotinib.
Carmustine	The metabolism of Erlotinib can be decreased when combined with Carmustine.
Carvedilol	The metabolism of Erlotinib can be decreased when combined with Carvedilol.
Cefradine	The serum concentration of Erlotinib can be decreased when it is combined with Cefradine.
Celecoxib	The metabolism of Erlotinib can be decreased when combined with Celecoxib.
Celiprolol	The metabolism of Erlotinib can be decreased when combined with Celiprolol.
Cenobamate	The serum concentration of Erlotinib can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Erlotinib can be decreased when combined with Cephalexin.
Ceritinib	The metabolism of Erlotinib can be decreased when combined with Ceritinib.
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Erlotinib.
Certolizumab	The metabolism of Erlotinib can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Erlotinib.
Cevimeline	The metabolism of Erlotinib can be decreased when combined with Cevimeline.
Chloramphenicol	The metabolism of Erlotinib can be decreased when combined with Chloramphenicol.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Erlotinib.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Chloroprocaine.
Chloroquine	The metabolism of Erlotinib can be decreased when combined with Chloroquine.
Chlorpheniramine	The metabolism of Erlotinib can be decreased when combined with Chlorpheniramine.
Chlorpromazine	The serum concentration of Erlotinib can be decreased when it is combined with Chlorpromazine.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Erlotinib.
Chlorzoxazone	The metabolism of Erlotinib can be decreased when combined with Chlorzoxazone.
Cholecalciferol	The metabolism of Erlotinib can be decreased when combined with Cholecalciferol.
Ciclesonide	The metabolism of Erlotinib can be decreased when combined with Ciclesonide.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Erlotinib.
Cimetidine	Cimetidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinacalcet	The metabolism of Erlotinib can be decreased when combined with Cinacalcet.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Cinchocaine.
Cinnarizine	The metabolism of Erlotinib can be decreased when combined with Cinnarizine.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Erlotinib.
Ciprofloxacin	The serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.
Cisapride	The metabolism of Erlotinib can be decreased when combined with Cisapride.
Citalopram	The metabolism of Erlotinib can be decreased when combined with Citalopram.
Cladribine	Erlotinib may decrease the excretion rate of Cladribine which could result in a higher serum level.
Clarithromycin	The metabolism of Erlotinib can be decreased when combined with Clarithromycin.
Clemastine	The metabolism of Erlotinib can be decreased when combined with Clemastine.
Clevidipine	The serum concentration of Erlotinib can be decreased when it is combined with Clevidipine.
Clindamycin	The metabolism of Erlotinib can be decreased when combined with Clindamycin.
Clobazam	The serum concentration of Erlotinib can be decreased when it is combined with Clobazam.
Clobetasol	The serum concentration of Erlotinib can be decreased when it is combined with Clobetasol propionate.
Clofarabine	Erlotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The metabolism of Erlotinib can be decreased when combined with Clofazimine.
Clofibrate	The serum concentration of Erlotinib can be decreased when it is combined with Clofibrate.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Erlotinib.
Clonidine	The metabolism of Clonidine can be decreased when combined with Erlotinib.
Clopidogrel	The metabolism of Erlotinib can be decreased when combined with Clopidogrel.
Clozapine	The serum concentration of Erlotinib can be decreased when it is combined with Clozapine.
Cobicistat	The metabolism of Erlotinib can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Cobimetinib can be decreased when combined with Erlotinib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Cocaine.
Codeine	The metabolism of Erlotinib can be decreased when combined with Codeine.
Colchicine	The metabolism of Colchicine can be decreased when combined with Erlotinib.
Conivaptan	The metabolism of Erlotinib can be decreased when combined with Conivaptan.
Conjugated estrogens	The metabolism of Erlotinib can be decreased when combined with Conjugated estrogens.
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Erlotinib.
Corticotropin	The serum concentration of Erlotinib can be decreased when it is combined with Corticotropin.

You Might Also Read Ketotifen; Uses, Dosage, Side Effects, Drug Interactions

Cortisone acetate	The serum concentration of Erlotinib can be decreased when it is combined with Cortisone acetate.
Crizotinib	The metabolism of Erlotinib can be decreased when combined with Crizotinib.
Curcumin	The metabolism of Erlotinib can be decreased when combined with Curcumin.
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Erlotinib.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Erlotinib.
Cyclophosphamide	The serum concentration of Erlotinib can be decreased when it is combined with Cyclophosphamide.
Cyclosporine	The metabolism of Erlotinib can be decreased when combined with Cyclosporine.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Erlotinib.
Cyproterone acetate	The metabolism of Erlotinib can be increased when combined with Cyproterone acetate.
Dabrafenib	The serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.
Dacarbazine	The metabolism of Dacarbazine can be decreased when combined with Erlotinib.
Daclatasvir	The metabolism of Erlotinib can be decreased when combined with Daclatasvir.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Erlotinib.
Dactinomycin	Erlotinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level.
Dalfopristin	The metabolism of Erlotinib can be decreased when combined with Dalfopristin.
Danazol	The metabolism of Erlotinib can be decreased when combined with Danazol.
Dapagliflozin	The metabolism of Erlotinib can be decreased when combined with Dapagliflozin.
Dapsone	The metabolism of Erlotinib can be decreased when combined with Dapsone.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erlotinib.
Darifenacin	The metabolism of Erlotinib can be decreased when combined with Darifenacin.
Darolutamide	Erlotinib may decrease the excretion rate of Darolutamide which could result in a higher serum level.
Darunavir	The serum concentration of Erlotinib can be increased when it is combined with Darunavir.
Dasabuvir	The metabolism of Erlotinib can be decreased when combined with Dasabuvir.
Dasatinib	The metabolism of Erlotinib can be decreased when combined with Dasatinib.
Daunorubicin	The metabolism of Erlotinib can be decreased when combined with Daunorubicin.
Debrisoquine	The metabolism of Erlotinib can be decreased when combined with Debrisoquine.
Deferasirox	The serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.
Deflazacort	The metabolism of Erlotinib can be increased when combined with Deflazacort.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erlotinib.
Delafloxacin	The serum concentration of Erlotinib can be decreased when it is combined with Delafloxacin.
Delamanid	Erlotinib may increase the QTc-prolonging activities of Delamanid.
Delavirdine	The metabolism of Erlotinib can be decreased when combined with Delavirdine.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Erlotinib.
Desipramine	The metabolism of Erlotinib can be decreased when combined with Desipramine.
Desloratadine	The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Erlotinib.
Desvenlafaxine	The metabolism of Erlotinib can be decreased when combined with Desvenlafaxine.
Deutetrabenazine	The metabolism of Erlotinib can be decreased when combined with Deutetrabenazine.
Dexamethasone	The metabolism of Erlotinib can be increased when combined with Dexamethasone.
Dexamethasone	The serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone acetate.
Dexbromphenir	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erlotinib.
Dexchlorphenira	The metabolism of Erlotinib can be decreased when combined with Dexchlorpheniramine maleate.
Dexfenfluramine	The metabolism of Erlotinib can be decreased when combined with Dexfenfluramine.
Dexibuprofen	The metabolism of Erlotinib can be decreased when combined with Dexibuprofen.
Dexlansoprazole	Dexlansoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexmedetomidine	The metabolism of Erlotinib can be decreased when combined with Dexmedetomidine.
Dextroamphetamine	The metabolism of Erlotinib can be decreased when combined with Dextroamphetamine.
Dextromethorphan	The metabolism of Erlotinib can be decreased when combined with Dextromethorphan.
Dextropropox	The metabolism of Erlotinib can be decreased when combined with Dextropropoxyphene.
Diacerein	The metabolism of Erlotinib can be decreased when combined with Diacerein.
Diazepam	The metabolism of Erlotinib can be decreased when combined with Diazepam.
Diclofenac	The metabolism of Erlotinib can be decreased when combined with Diclofenac.
Dicloxacillin	The serum concentration of Erlotinib can be decreased when it is combined with Dicloxacillin.
Dicoumarol	The serum concentration of Dicoumarol can be increased when it is combined with Erlotinib.
Diethylstilbestrol	The metabolism of Erlotinib can be decreased when combined with Diethylstilbestrol.
Difluocortolone	The metabolism of Erlotinib can be increased when combined with Difluocortolone.
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Erlotinib.
Digoxin	The risk or severity of QTc prolongation can be increased when Digoxin is combined with Erlotinib.
Dihydralazine	The metabolism of Erlotinib can be decreased when combined with Dihydralazine.
Dihydrocodeine	The metabolism of Erlotinib can be decreased when combined with Dihydrocodeine.
Dihydroergocornine	The metabolism of Erlotinib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine	The metabolism of Erlotinib can be decreased when combined with Dihydroergocristine.
Dihydroergotamine	The metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.
Diltiazem	The metabolism of Erlotinib can be decreased when combined with Diltiazem.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Erlotinib.
Dimethyl sulfoxide	The metabolism of Erlotinib can be decreased when combined with Dimethyl sulfoxide.
Diosmin	The metabolism of Erlotinib can be decreased when combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Diphenhydramine.
Disopyramide	The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Erlotinib.
Disulfiram	The metabolism of Erlotinib can be decreased when combined with Disulfiram.
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Erlotinib.
Dofetilide	The metabolism of Dofetilide can be decreased when combined with Erlotinib.
Dolasetron	The metabolism of Erlotinib can be decreased when combined with Dolasetron.
Dolutegravir	Erlotinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Domperidone	The metabolism of Erlotinib can be decreased when combined with Domperidone.
Donepezil	The metabolism of Erlotinib can be decreased when combined with Donepezil.
Doravirine	The metabolism of Erlotinib can be decreased when combined with Doravirine.
Dosulepin	The metabolism of Erlotinib can be decreased when combined with Dosulepin.
Doxazosin	The metabolism of Erlotinib can be decreased when combined with Doxazosin.
Doxepin	Doxepin can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Erlotinib.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Erlotinib.
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Erlotinib.
Dronedarone	Erlotinib may increase the QTc-prolonging activities of Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Erlotinib.
Drospirenone	The metabolism of Erlotinib can be decreased when combined with Drospirenone.
Duloxetine	The metabolism of Erlotinib can be decreased when combined with Duloxetine.
Dutasteride	The metabolism of Erlotinib can be decreased when combined with Dutasteride.
Duvelisib	The metabolism of Erlotinib can be decreased when combined with Duvelisib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Dyclonine.
Ebastine	The metabolism of Erlotinib can be decreased when combined with Ebastine.
Echinacea	The metabolism of Erlotinib can be increased when combined with Echinacea.
Efavirenz	The metabolism of Erlotinib can be decreased when combined with Efavirenz.
Elagolix	The metabolism of Erlotinib can be decreased when combined with Elagolix.
Elbasvir	The metabolism of Erlotinib can be decreased when combined with Elbasvir.
Eletriptan	The metabolism of Erlotinib can be decreased when combined with Eletriptan.
Elexacaftor	The metabolism of Erlotinib can be decreased when combined with Elexacaftor.
Eliglustat	The metabolism of Eliglustat can be decreased when combined with Erlotinib.
Eltrombopag	The metabolism of Erlotinib can be decreased when combined with Eltrombopag.
Elvitegravir	The metabolism of Erlotinib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Erlotinib can be increased when combined with Emapalumab.

medastine	The risk or severity of QTc prolongation can be increased when Emedastine is combined with Erlotinib.
Enasidenib	The serum concentration of Erlotinib can be decreased when it is combined with Enasidenib.
Encainide	The metabolism of Erlotinib can be decreased when combined with Encainide.
Encorafenib	The metabolism of Erlotinib can be decreased when combined with Encorafenib.
Enoxacin	The metabolism of Erlotinib can be decreased when combined with Enoxacin.
Entacapone	The metabolism of Erlotinib can be decreased when combined with Entacapone.
Entecavir	The metabolism of Erlotinib can be decreased when combined with Entecavir.
Entrectinib	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Entrectinib.
Enzalutamide	The metabolism of Erlotinib can be increased when combined with Enzalutamide.
Epinastine	Epinastine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Epinephrine	The metabolism of Erlotinib can be decreased when combined with Epinephrine.
Eplerenone	The metabolism of Erlotinib can be decreased when combined with Eplerenone.
Erdafitinib	The metabolism of Erdafitinib can be decreased when combined with Erlotinib.
Ergotamine	The metabolism of Erlotinib can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erlotinib.
Ertugliflozin	Erlotinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.
Erythromycin	The metabolism of Erlotinib can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Erlotinib.
Escitalopram	The serum concentration of Erlotinib can be increased when it is combined with Escitalopram.
Esketamine	The serum concentration of Erlotinib can be decreased when it is combined with Esketamine.
Eslicarbazepine	The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine.
Eslicarbazepine acetate	The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine acetate.
Esmolol	The metabolism of Erlotinib can be decreased when combined with Esmolol.
Esomeprazole	Esomeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Estetrol	The metabolism of Erlotinib can be decreased when combined with Estetrol.
Estradiol	The metabolism of Erlotinib can be decreased when combined with Estradiol.
Estradiol acetate	The serum concentration of Erlotinib can be decreased when it is combined with Estradiol acetate.
Estradiol benzoate	The serum concentration of Erlotinib can be decreased when it is combined with Estradiol benzoate.
Estradiol cypionate	The serum concentration of Erlotinib can be decreased when it is combined with Estradiol cypionate.
Estradiol dienanthate	The serum concentration of Erlotinib can be decreased when it is combined with Estradiol dienanthate.
Estradiol valerate	The serum concentration of Erlotinib can be decreased when it is combined with Estradiol valerate.
Estrone sulfate	The metabolism of Erlotinib can be decreased when combined with Estrone sulfate.
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Erlotinib.
Etanercept	The metabolism of Erlotinib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Erlotinib can be decreased when combined with Ethambutol.
Ethanol	The serum concentration of Erlotinib can be decreased when it is combined with Ethanol.
Ethinylestradiol	The metabolism of Erlotinib can be decreased when combined with Ethinylestradiol.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Erlotinib.
Ethotoin	The serum concentration of Erlotinib can be decreased when it is combined with Ethotoin.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Etidocaine.
Etoposide	The serum concentration of Erlotinib can be decreased when it is combined with Etoposide.
Etoricoxib	The metabolism of Erlotinib can be decreased when combined with Etoricoxib.
Etravirine	The serum concentration of Erlotinib can be decreased when it is combined with Etravirine.
Everolimus	The metabolism of Everolimus can be decreased when combined with Erlotinib.
Ezetimibe	Erlotinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Erlotinib.
Famotidine	Famotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Favipiravir	The metabolism of Erlotinib can be decreased when combined with Favipiravir.
Febuxostat	The metabolism of Febuxostat can be decreased when combined with Erlotinib.
Fedratinib	The metabolism of Erlotinib can be decreased when combined with Fedratinib.
Felbamate	The serum concentration of Erlotinib can be decreased when it is combined with Felbamate.
Felodipine	The metabolism of Erlotinib can be decreased when combined with Felodipine.
Fenfluramine	The metabolism of Erlotinib can be decreased when combined with Fenfluramine.
Fenofibrate	The metabolism of Erlotinib can be decreased when combined with Fenofibrate.
Fentanyl	The metabolism of Fentanyl can be decreased when combined with Erlotinib.
Fesoterodine	The metabolism of Erlotinib can be decreased when combined with Fesoterodine.
Fexinidazole	The risk or severity of adverse effects can be increased when Erlotinib is combined with Fexinidazole.
Filgotinib	The serum concentration of Erlotinib can be increased when it is combined with Filgotinib.
Finasteride	The metabolism of Erlotinib can be decreased when combined with Finasteride.
Finerenone	The serum concentration of Finerenone can be increased when it is combined with Erlotinib.
Flecainide	The metabolism of Erlotinib can be decreased when combined with Flecainide.
Flucloxacillin	The serum concentration of Erlotinib can be decreased when it is combined with Flucloxacillin.
Fluconazole	The metabolism of Erlotinib can be decreased when combined with Fluconazole.
Fluindione	The serum concentration of Fluindione can be increased when it is combined with Erlotinib.
Flunarizine	The metabolism of Erlotinib can be decreased when combined with Flunarizine.
Flunisolide	The serum concentration of Erlotinib can be decreased when it is combined with Flunisolide.
Fluocinolone acetonide	The serum concentration of Erlotinib can be decreased when it is combined with Fluocinolone acetonide.
Fluocinonide	The metabolism of Erlotinib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Erlotinib can be increased when combined with Fluocortolone.
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Erlotinib.
Fluoxetine	The serum concentration of Erlotinib can be increased when it is combined with Fluoxetine.
Flupentixol	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Flupentixol.
Fluphenazine	The metabolism of Erlotinib can be decreased when combined with Fluphenazine.
Flurbiprofen	The metabolism of Flurbiprofen can be decreased when combined with Erlotinib.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Erlotinib.
Flutamide	The metabolism of Erlotinib can be decreased when combined with Flutamide.
Fluticasone	The metabolism of Erlotinib can be increased when combined with Fluticasone.
Fluticasone furoate	The metabolism of Erlotinib can be increased when combined with Fluticasone furoate.
Fluticasone	The metabolism of Erlotinib can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Erlotinib.
Fluvoxamine	The metabolism of Erlotinib can be decreased when combined with Fluvoxamine.
Folic acid	Erlotinib may decrease the excretion rate of Folic acid which could result in a higher serum level.
Follitropin	The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib.
Formestane	The serum concentration of Erlotinib can be decreased when it is combined with Formestane.
Formoterol	The metabolism of Erlotinib can be decreased when combined with Formoterol.
Fosamprenavir	The metabolism of Erlotinib can be decreased when combined with Fosamprenavir.
Fosaprepitant	The serum concentration of Erlotinib can be decreased when it is combined with Fosaprepitant.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Erlotinib.
Fosnetupitant	The metabolism of Erlotinib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Erlotinib can be increased when combined with Fosphenytoin.
Fostamatinib	The metabolism of Erlotinib can be decreased when combined with Fostamatinib.
Fostemsavir	The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Erlotinib.
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Erlotinib.
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Erlotinib.
Furosemide	The metabolism of Furosemide can be decreased when combined with Erlotinib.
Fusidic acid	The metabolism of Erlotinib can be decreased when combined with Fusidic acid.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Erlotinib.
Galantamine	The metabolism of Erlotinib can be decreased when combined with Galantamine.
Gatifloxacin	The metabolism of Erlotinib can be decreased when combined with Gatifloxacin.

Gefitinib	The metabolism of Erlotinib can be decreased when combined with Gefitinib.
Gemfibrozil	The metabolism of Erlotinib can be decreased when combined with Gemfibrozil.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Erlotinib.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Erlotinib.
Ginkgo biloba	The metabolism of Erlotinib can be decreased when combined with Ginkgo biloba.
Givosiran	The serum concentration of Erlotinib can be increased when it is combined with Givosiran.
Glasdegib	The metabolism of Erlotinib can be decreased when combined with Glasdegib.
Glecaprevir	The metabolism of Erlotinib can be decreased when combined with Glecaprevir.
Glipizide	The metabolism of Glipizide can be decreased when combined with Erlotinib.
Glyburide	The metabolism of Erlotinib can be decreased when combined with Glyburide.
Glycerol	The serum concentration of Erlotinib can be decreased when it is combined with Glycerol phenylbutyrate.
Golimumab	The metabolism of Erlotinib can be increased when combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib.
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Erlotinib.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Erlotinib.
Griseofulvin	The serum concentration of Erlotinib can be decreased when it is combined with Griseofulvin.
Guanabenz	The metabolism of Guanabenz can be decreased when combined with Erlotinib.
Halofantrine	The metabolism of Erlotinib can be decreased when combined with Halofantrine.
Haloperidol	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Haloperidol.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Erlotinib.
Hydralazine	The metabolism of Erlotinib can be decreased when combined with Hydralazine.
Hydrochlorothiazide	The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Erlotinib.
Hydrocodone	The metabolism of Erlotinib can be decreased when combined with Hydrocodone.
Hydrocortamate	The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortamate.
Hydrocortisone	The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone.
Hydrocortisone acet	The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone acetate.
Hydrocortisone bu	The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone butyrate.
Hydrocortisone	The metabolism of Erlotinib can be decreased when combined with Hydrocortisone cypionate.
Hydrocortisone	The metabolism of Erlotinib can be decreased when combined with Hydrocortisone phosphate.
Hydrocortisone	The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone succinate.
Hydrotalcite	Hydrotalcite can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxychloroquine	The metabolism of Erlotinib can be decreased when combined with Hydroxychloroquine.
Hydroxyprogeste	The metabolism of Erlotinib can be decreased when combined with Hydroxyprogesterone caproate.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Erlotinib.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Erlotinib.
Ibuprofen	The metabolism of Erlotinib can be decreased when combined with Ibuprofen.
Ibutilide	The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Erlotinib.
Idarubicin	The metabolism of Erlotinib can be decreased when combined with Idarubicin.
Idelalisib	The metabolism of Idelalisib can be decreased when combined with Erlotinib.
Ifosfamide	The serum concentration of Erlotinib can be decreased when it is combined with Ifosfamide.
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Erlotinib.
Imatinib	The serum concentration of Erlotinib can be increased when it is combined with Imatinib.
Imipramine	The metabolism of Erlotinib can be decreased when combined with Imipramine.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Erlotinib.
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Erlotinib.
Indinavir	The metabolism of Erlotinib can be decreased when combined with Indinavir.
Indomethacin	The metabolism of Indomethacin can be decreased when combined with Erlotinib.
Infigratinib	The metabolism of Erlotinib can be decreased when combined with Infigratinib.
Infliximab	The metabolism of Erlotinib can be increased when combined with Infliximab.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Erlotinib.
Insulin beef	The metabolism of Erlotinib can be increased when combined with Insulin beef.
Insulin pork	The metabolism of Erlotinib can be increased when combined with Insulin pork.
Interferon alfa-2a	The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2a.
Interferon alfa-2b	The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2b.
Interferon alfa-n1	The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n1.
Interferon alfa-n3	The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n3.
Interferon alfa	The metabolism of Erlotinib can be decreased when combined with Interferon alfacon-1.
Interferon beta-1a	The metabolism of Erlotinib can be decreased when combined with Interferon beta-1a.
Interferon beta-1b	The metabolism of Erlotinib can be decreased when combined with Interferon beta-1b.
Interferon	The metabolism of Erlotinib can be decreased when combined with Interferon gamma-1b.
Ipecac	The metabolism of Erlotinib can be decreased when combined with Ipecac.
Irbesartan	The metabolism of Erlotinib can be decreased when combined with Irbesartan.
Irinotecan	The risk or severity of neutropenia can be increased when Erlotinib is combined with Irinotecan.
Isavuconazole	The serum concentration of Erlotinib can be decreased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Erlotinib can be decreased when it is combined with Isavuconazonium.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Erlotinib.
Isoniazid	The metabolism of Erlotinib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Erlotinib can be decreased when combined with Isradipine.
Istradefylline	The metabolism of Erlotinib can be decreased when combined with Istradefylline.
Itraconazole	The metabolism of Erlotinib can be decreased when combined with Itraconazole.
Ivabradine	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivabradine.
Ivacaftor	The metabolism of Erlotinib can be decreased when combined with Ivacaftor.
Ivermectin	Erlotinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivosidenib.
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Erlotinib.
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Erlotinib.
Ketamine	The serum concentration of Erlotinib can be decreased when it is combined with Ketamine.
Ketazolam	The metabolism of Erlotinib can be decreased when combined with Ketazolam.
Ketoconazole	The metabolism of Erlotinib can be decreased when combined with Ketoconazole.
Ketoprofen	The metabolism of Erlotinib can be decreased when combined with Ketoprofen.
Ketorolac	The metabolism of Erlotinib can be decreased when combined with Ketorolac.
Labetalol	The metabolism of Erlotinib can be decreased when combined with Labetalol.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Erlotinib.
Lacosamide	The metabolism of Erlotinib can be decreased when combined with Lacosamide.
Lamivudine	Erlotinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Erlotinib.
Lanreotide	The metabolism of Erlotinib can be decreased when combined with Lanreotide.
Lansoprazole	Lansoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lapatinib	The metabolism of Erlotinib can be decreased when combined with Lapatinib.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Erlotinib.
Leflunomide	The serum concentration of Erlotinib can be decreased when it is combined with Leflunomide.
Lemborexant	The metabolism of Erlotinib can be decreased when combined with Lemborexant.
Lenvatinib	The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Erlotinib.
Lercanidipine	The metabolism of Erlotinib can be decreased when combined with Lercanidipine.
Lesinurad	The metabolism of Erlotinib can be increased when combined with Lesinurad.
Letermovir	The metabolism of Erlotinib can be decreased when combined with Letermovir.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib.
Levacetylmeth	The metabolism of Levacetylmethadol can be decreased when combined with Erlotinib.

You Might Also Read Propylthiouracil - Uses, Dosage, Side Effects

Levamlodipine	The serum concentration of Levamlodipine can be increased when it is combined with Erlotinib.
Levobetaxolol	The metabolism of Erlotinib can be decreased when combined with Levobetaxolol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Erlotinib.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Erlotinib.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Erlotinib.
Levoketoconazole	The metabolism of Erlotinib can be decreased when combined with Levoketoconazole.
Levomenthol	The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Erlotinib.
Levomilnacipran	The metabolism of Erlotinib can be decreased when combined with Levomilnacipran.
Levonorgestrel	The metabolism of Erlotinib can be decreased when combined with Levonorgestrel.
Levosimendan	The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Erlotinib.
Levothyroxine	The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Erlotinib.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Erlotinib.
Linagliptin	The metabolism of Erlotinib can be decreased when combined with Linagliptin.
Linzagolix	The serum concentration of Erlotinib can be increased when it is combined with Linzagolix.
Liothyronine	The therapeutic efficacy of Liothyronine can be decreased when used in combination with Erlotinib.
Liotrix	The therapeutic efficacy of Liotrix can be decreased when used in combination with Erlotinib.
Lisdexamfetamine	The metabolism of Erlotinib can be decreased when combined with Lisdexamfetamine.
Lisuride	The metabolism of Erlotinib can be decreased when combined with Lisuride.
Lofexidine	The metabolism of Erlotinib can be decreased when combined with Lofexidine.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Erlotinib.
Lomitapide	The metabolism of Erlotinib can be decreased when combined with Lomitapide.
Lonafarnib	The metabolism of Erlotinib can be decreased when combined with Lonafarnib.
Lonapegsomatr	The metabolism of Erlotinib can be increased when combined with Lonapegsomatropin.
Loperamide	The metabolism of Loperamide can be decreased when combined with Erlotinib.
Lopinavir	The metabolism of Erlotinib can be decreased when combined with Lopinavir.
Loratadine	The metabolism of Erlotinib can be decreased when combined with Loratadine.
Lorcaserin	The metabolism of Erlotinib can be decreased when combined with Lorcaserin.
Lorlatinib	The serum concentration of Erlotinib can be decreased when it is combined with Lorlatinib.
Lorpiprazole	The metabolism of Erlotinib can be decreased when combined with Lorpiprazole.
Losartan	The metabolism of Erlotinib can be decreased when combined with Losartan.
Lovastatin	The metabolism of Lovastatin can be decreased when combined with Erlotinib.
Lumacaftor	The metabolism of Erlotinib can be increased when combined with Lumacaftor.
Lumateperone	The serum concentration of Lumateperone can be increased when it is combined with Erlotinib.
Lumefantrine	The metabolism of Erlotinib can be decreased when combined with Lumefantrine.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Erlotinib.
Lusutrombopag	Erlotinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Macimorelin	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Macimorelin.
Magaldrate	Magaldrate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium	Magnesium carbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium	Magnesium hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate	Magnesium silicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium	Magnesium trisilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Manidipine	The metabolism of Erlotinib can be decreased when combined with Manidipine.
Maprotiline	The metabolism of Erlotinib can be decreased when combined with Maprotiline.
Mavacamten	The serum concentration of Erlotinib can be decreased when it is combined with Mavacamten.
Meclizine	The metabolism of Erlotinib can be decreased when combined with Meclizine.
Medroxyprogester	The serum concentration of Erlotinib can be decreased when it is combined with Medroxyprogesterone acetate.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Erlotinib.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Erlotinib.
Melatonin	The metabolism of Melatonin can be decreased when combined with Erlotinib.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Meloxicam.
Meperidine	The metabolism of Erlotinib can be decreased when combined with Meperidine.
Mephenytoin	The metabolism of Erlotinib can be decreased when combined with Mephenytoin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Mepivacaine.
Meprednisone	The metabolism of Erlotinib can be increased when combined with Meprednisone.
Mepyramine	The metabolism of Erlotinib can be decreased when combined with Mepyramine.
Mesoridazine	The metabolism of Erlotinib can be decreased when combined with Mesoridazine.
Mestranol	The metabolism of Erlotinib can be decreased when combined with Mestranol.
Metamfetamine	The metabolism of Erlotinib can be decreased when combined with Metamfetamine.
Methadone	The metabolism of Erlotinib can be decreased when combined with Methadone.
Methantheline	Methantheline can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methimazole	The metabolism of Erlotinib can be decreased when combined with Methimazole.
Methotrexate	The metabolism of Methotrexate can be decreased when combined with Erlotinib.
Methotrimeprazine	The metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.
Methoxsalen	The metabolism of Erlotinib can be decreased when combined with Methoxsalen.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erlotinib.
Methoxyflurane	The metabolism of Erlotinib can be decreased when combined with Methoxyflurane.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Erlotinib.
Methylene blue	The metabolism of Erlotinib can be decreased when combined with Methylene blue.
Methylergometrine	The metabolism of Erlotinib can be decreased when combined with Methylergometrine.
Methylphenobarbital	The serum concentration of Erlotinib can be decreased when it is combined with Methylphenobarbital.
Methylprednisolone	The serum concentration of Erlotinib can be decreased when it is combined with Methylprednisolone.
Methylprednisone	The metabolism of Erlotinib can be decreased when combined with Methylprednisone.
Methysergide	The metabolism of Erlotinib can be decreased when combined with Methysergide.
Metoclopramide	The metabolism of Erlotinib can be decreased when combined with Metoclopramide.
Metoprolol	The metabolism of Erlotinib can be decreased when combined with Metoprolol.
Metreleptin	The metabolism of Erlotinib can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Erlotinib can be decreased when combined with Metronidazole.
Metyrapone	The serum concentration of Erlotinib can be decreased when it is combined with Metyrapone.
Mexiletine	The metabolism of Erlotinib can be decreased when combined with Mexiletine.
Mianserin	The metabolism of Erlotinib can be decreased when combined with Mianserin.
Miconazole	The metabolism of Erlotinib can be decreased when combined with Miconazole.
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Erlotinib.
Midostaurin	The metabolism of Erlotinib can be decreased when combined with Midostaurin.
Mifepristone	The serum concentration of Erlotinib can be increased when it is combined with Mifepristone.
Migalastat	The metabolism of Migalastat can be decreased when combined with Erlotinib.
Milnacipran	The metabolism of Erlotinib can be decreased when combined with Milnacipran.
Minaprine	The metabolism of Erlotinib can be decreased when combined with Minaprine.
Minoxidil	The metabolism of Minoxidil can be decreased when combined with Erlotinib.
Miocamycin	The metabolism of Erlotinib can be decreased when combined with Miocamycin.
Mirabegron	The serum concentration of Erlotinib can be increased when it is combined with Mirabegron.
Mirtazapine	The metabolism of Erlotinib can be decreased when combined with Mirtazapine.
Mitapivat	The serum concentration of Erlotinib can be decreased when it is combined with Mitapivat.
Mitotane	The metabolism of Erlotinib can be increased when combined with Mitotane.
Mitoxantrone	Erlotinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.
Mizolastine	The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Erlotinib.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Mobocertinib.

Moclobemide	The metabolism of Erlotinib can be decreased when combined with Moclobemide.
Modafinil	The serum concentration of Erlotinib can be decreased when it is combined with Modafinil.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Erlotinib.
Mometasone	The metabolism of Erlotinib can be increased when combined with Mometasone furoate.
Montelukast	The metabolism of Erlotinib can be decreased when combined with Montelukast.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Erlotinib.
Morphine	The metabolism of Erlotinib can be decreased when combined with Morphine.
Mosunetuzumab	The metabolism of Erlotinib can be decreased when combined with Mosunetuzumab.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Erlotinib.
Mycophenolate	The metabolism of Erlotinib can be decreased when combined with Mycophenolate mofetil.
Mycophenolic acid	The metabolism of Mycophenolic acid can be decreased when combined with Erlotinib.
Nabumetone	The metabolism of Erlotinib can be decreased when combined with Nabumetone.
Nadolol	The metabolism of Erlotinib can be decreased when combined with Nadolol.
Nafcillin	The serum concentration of Erlotinib can be decreased when it is combined with Nafcillin.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Erlotinib.
Naloxone	The metabolism of Erlotinib can be decreased when combined with Naloxone.
Naltrexone	The metabolism of Naltrexone can be decreased when combined with Erlotinib.
Naproxen	The metabolism of Erlotinib can be decreased when combined with Naproxen.
Nateglinide	The metabolism of Erlotinib can be decreased when combined with Nateglinide.
Nebivolol	The metabolism of Erlotinib can be decreased when combined with Nebivolol.
Nefazodone	The metabolism of Erlotinib can be decreased when combined with Nefazodone.
Nelfinavir	The metabolism of Erlotinib can be decreased when combined with Nelfinavir.
Neratinib	The metabolism of Neratinib can be decreased when combined with Erlotinib.
Netupitant	The metabolism of Erlotinib can be decreased when combined with Netupitant.
Nevirapine	The metabolism of Erlotinib can be decreased when combined with Nevirapine.
Niacin	The metabolism of Erlotinib can be decreased when combined with Niacin.
Nicardipine	The metabolism of Erlotinib can be decreased when combined with Nicardipine.
Nicergoline	The metabolism of Erlotinib can be decreased when combined with Nicergoline.
Niclosamide	The metabolism of Erlotinib can be decreased when combined with Niclosamide.
Nifedipine	The serum concentration of Erlotinib can be decreased when it is combined with Nifedipine.
Nilotinib	The metabolism of Erlotinib can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Erlotinib can be decreased when combined with Nilutamide.
Nilvadipine	The metabolism of Erlotinib can be decreased when combined with Nilvadipine.
Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Erlotinib.
Nintedanib	The metabolism of Erlotinib can be decreased when combined with Nintedanib.
Nisoldipine	The metabolism of Erlotinib can be decreased when combined with Nisoldipine.
Nitrendipine	The metabolism of Erlotinib can be decreased when combined with Nitrendipine.
Nitrofurantoin	Erlotinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nizatidine	Nizatidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norethisterone	The metabolism of Erlotinib can be decreased when combined with Norethisterone.
Norfloxacin	The metabolism of Erlotinib can be decreased when combined with Norfloxacin.
Norgestimate	The serum concentration of Erlotinib can be decreased when it is combined with Norgestimate.
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Erlotinib.
Noscapine	The metabolism of Erlotinib can be decreased when combined with Noscapine.
Obeticholic acid	The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Erlotinib.
Octreotide	The serum concentration of Erlotinib can be increased when it is combined with Octreotide.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Erlotinib.
Olanzapine	Olanzapine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Olaparib	The metabolism of Erlotinib can be decreased when combined with Olaparib.
Oliceridine	The metabolism of Erlotinib can be decreased when combined with Oliceridine.
Olodaterol	The metabolism of Erlotinib can be decreased when combined with Olodaterol.
Ombitasvir	The metabolism of Erlotinib can be decreased when combined with Ombitasvir.
Omeprazole	Omeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ondansetron	The metabolism of Erlotinib can be decreased when combined with Ondansetron.
Opium	The metabolism of Erlotinib can be decreased when combined with Opium.
Oritavancin	The serum concentration of Erlotinib can be decreased when it is combined with Oritavancin.
Orphenadrine	The metabolism of Erlotinib can be decreased when combined with Orphenadrine.
Osilodrostat	The serum concentration of Erlotinib can be increased when it is combined with Osilodrostat.
Osimertinib	The serum concentration of Erlotinib can be decreased when it is combined with Osimertinib.
Ospemifene	The metabolism of Erlotinib can be decreased when combined with Ospemifene.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Erlotinib.
Oxamniquine	The metabolism of Erlotinib can be decreased when combined with Oxamniquine.
Oxatomide	The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Erlotinib.
Oxcarbazepine	The serum concentration of Erlotinib can be decreased when it is combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Oxetacaine.
Oxprenolol	The metabolism of Erlotinib can be decreased when combined with Oxprenolol.
Oxtriphylline	The metabolism of Oxtriphylline can be decreased when combined with Erlotinib.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Oxybuprocaine.
Oxybutynin	The metabolism of Erlotinib can be decreased when combined with Oxybutynin.
Oxycodone	The metabolism of Erlotinib can be decreased when combined with Oxycodone.
Oxymorphone	The metabolism of Erlotinib can be decreased when combined with Oxymorphone.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib.
Ozanimod	The metabolism of Ozanimod can be decreased when combined with Erlotinib.
Paclitaxel	The serum concentration of Erlotinib can be decreased when it is combined with Paclitaxel.
Pacritinib	The serum concentration of Erlotinib can be increased when it is combined with Pacritinib.
Palbociclib	The metabolism of Erlotinib can be decreased when combined with Palbociclib.
Paliperidone	The metabolism of Erlotinib can be decreased when combined with Paliperidone.
Palonosetron	The metabolism of Erlotinib can be decreased when combined with Palonosetron.
Panobinostat	The metabolism of Erlotinib can be decreased when combined with Panobinostat.
Pantoprazole	Pantoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Erlotinib.
Paramethadione	The metabolism of Erlotinib can be decreased when combined with Paramethadione.
Parathyroid hormone	The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Erlotinib.
Paritaprevir	The metabolism of Erlotinib can be decreased when combined with Paritaprevir.
Paroxetine	The metabolism of Erlotinib can be decreased when combined with Paroxetine.
Pasireotide	The metabolism of Erlotinib can be decreased when combined with Pasireotide.
Pazopanib	The metabolism of Erlotinib can be decreased when combined with Pazopanib.
Pefloxacin	The metabolism of Erlotinib can be decreased when combined with Pefloxacin.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Erlotinib.
Peginterferon a	The metabolism of Erlotinib can be decreased when combined with Peginterferon alfa-2a.
Peginterferon	The serum concentration of Erlotinib can be increased when it is combined with Peginterferon alfa-2b.
Pegvisomant	The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant.
Pemetrexed	The metabolism of Pemetrexed can be decreased when combined with Erlotinib.
Penbutolol	The metabolism of Erlotinib can be decreased when combined with Penbutolol.
Penciclovir	The metabolism of Erlotinib can be decreased when combined with Penciclovir.
Pentamidine	The metabolism of Erlotinib can be decreased when combined with Pentamidine.
Pentobarbital	The metabolism of Erlotinib can be increased when combined with Pentobarbital.
Pentoxifylline	The metabolism of Pentoxifylline can be decreased when combined with Erlotinib.
Perampanel	The serum concentration of Erlotinib can be decreased when it is combined with Perampanel.
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Erlotinib.

Perhexiline	The metabolism of Erlotinib can be decreased when combined with Perhexiline.
Perphenazine	The metabolism of Erlotinib can be decreased when combined with Perphenazine.
Pexidartinib	The metabolism of Pexidartinib can be decreased when combined with Erlotinib.
Phenformin	The metabolism of Erlotinib can be decreased when combined with Phenformin.
Phenindione	The serum concentration of Phenindione can be increased when it is combined with Erlotinib.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erlotinib.
Phenobarbital	The metabolism of Erlotinib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Phenol.
Phenprocoumon	The serum concentration of Phenprocoumon can be increased when it is combined with Erlotinib.
Phenylbutazone	The serum concentration of Erlotinib can be decreased when it is combined with Phenylbutazone.
Phenylbutyric acid	The metabolism of Erlotinib can be decreased when combined with Phenylbutyric acid.
Phenylephrine	The metabolism of Erlotinib can be increased when combined with Phenylephrine.
Phenytoin	The metabolism of Erlotinib can be increased when combined with Phenytoin.
Pibrentasvir	Erlotinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level.
Pimavanserin	The metabolism of Erlotinib can be decreased when combined with Pimavanserin.
Pimozide	The metabolism of Pimozide can be decreased when combined with Erlotinib.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Erlotinib.
Pindolol	The metabolism of Erlotinib can be decreased when combined with Pindolol.
Pioglitazone	The serum concentration of Pioglitazone can be increased when it is combined with Erlotinib.
Piperaquine	The metabolism of Erlotinib can be decreased when combined with Piperaquine.
Piperazine	The metabolism of Erlotinib can be decreased when combined with Piperazine.
Pipotiazine	The metabolism of Erlotinib can be decreased when combined with Pipotiazine.
Pirfenidone	The metabolism of Erlotinib can be decreased when combined with Pirfenidone.
Piroxicam	The metabolism of Erlotinib can be decreased when combined with Piroxicam.
Pitavastatin	The metabolism of Pitavastatin can be decreased when combined with Erlotinib.
Pitolisant	The serum concentration of Erlotinib can be decreased when it is combined with Pitolisant.
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Erlotinib.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Erlotinib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Erlotinib.
Posaconazole	The metabolism of Erlotinib can be decreased when combined with Posaconazole.
Potassium Iodide	The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Erlotinib.
Potassium	The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Erlotinib.
Practolol	The metabolism of Erlotinib can be decreased when combined with Practolol.
Pralatrexate	Erlotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralsetinib	The serum concentration of Erlotinib can be decreased when it is combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Pramocaine.
Pravastatin	The metabolism of Pravastatin can be decreased when combined with Erlotinib.
Praziquantel	The metabolism of Erlotinib can be decreased when combined with Praziquantel.
Prazosin	Erlotinib may decrease the excretion rate of Prazosin which could result in a higher serum level.
Prednisolone	The serum concentration of Erlotinib can be decreased when it is combined with Prednisolone.
Prednisolone	The serum concentration of Erlotinib can be decreased when it is combined with Prednisolone acetate.
Prednisolone phosphate	The metabolism of Erlotinib can be increased when combined with Prednisolone phosphate.
Prednisone	The metabolism of Erlotinib can be increased when combined with Prednisone acetate.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Erlotinib.
Prenylamine	The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Erlotinib.
Pretomanid	The metabolism of Erlotinib can be decreased when combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Prilocaine.
Primaquine	The metabolism of Erlotinib can be decreased when combined with Primaquine.
Primidone	The metabolism of Erlotinib can be increased when combined with Primidone.
Probenecid	The serum concentration of Erlotinib can be decreased when it is combined with Probenecid.
Probucol	The risk or severity of QTc prolongation can be increased when Probucol is combined with Erlotinib.
Procainamide	The metabolism of Procainamide can be decreased when combined with Erlotinib.
Procaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Procaine.
Prochlorperazine	The metabolism of Erlotinib can be decreased when combined with Prochlorperazine.
Progesterone	The serum concentration of Erlotinib can be decreased when it is combined with Progesterone.
Proguanil	The metabolism of Erlotinib can be decreased when combined with Proguanil.
Promazine	The metabolism of Erlotinib can be decreased when combined with Promazine.
Promethazine	Promethazine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Propafenone	The metabolism of Erlotinib can be decreased when combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Proparacaine.
Propofol	The metabolism of Erlotinib can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Propoxycaine.
Propranolol	The metabolism of Erlotinib can be decreased when combined with Propranolol.
Propylthiouracil	The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erlotinib.
Protirelin	The therapeutic efficacy of Protirelin can be decreased when used in combination with Erlotinib.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Erlotinib.
Prucalopride	The metabolism of Prucalopride can be decreased when combined with Erlotinib.
Pyrimethamine	The metabolism of Erlotinib can be decreased when combined with Pyrimethamine.
Quetiapine	The metabolism of Erlotinib can be decreased when combined with Quetiapine.
Quinidine	The metabolism of Erlotinib can be decreased when combined with Quinidine.
Quinine	The serum concentration of Erlotinib can be decreased when it is combined with Quinine.
Quinupristin	The metabolism of Erlotinib can be decreased when combined with Quinupristin.
Rabeprazole	Rabeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Raloxifene	The metabolism of Erlotinib can be decreased when combined with Raloxifene.
Raltegravir	The metabolism of Raltegravir can be decreased when combined with Erlotinib.
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Erlotinib.
Ranitidine	Ranitidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ranolazine	The serum concentration of Erlotinib can be increased when it is combined with Ranolazine.
Rasagiline	The metabolism of Rasagiline can be decreased when combined with Erlotinib.
Reboxetine	The metabolism of Erlotinib can be decreased when combined with Reboxetine.
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Erlotinib.
Relugolix	The metabolism of Erlotinib can be decreased when combined with Relugolix.
Remdesivir	The metabolism of Erlotinib can be decreased when combined with Remdesivir.
Remoxipride	The metabolism of Erlotinib can be decreased when combined with Remoxipride.
Repaglinide	The metabolism of Erlotinib can be decreased when combined with Repaglinide.
Reserpine	The metabolism of Erlotinib can be increased when combined with Reserpine.
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Erlotinib.
Revefenacin	The metabolism of Erlotinib can be decreased when combined with Revefenacin.
Ribociclib	The metabolism of Erlotinib can be decreased when combined with Ribociclib.
Rifabutin	The serum concentration of Erlotinib can be decreased when it is combined with Rifabutin.
Rifampicin	The metabolism of Erlotinib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Erlotinib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Erlotinib can be increased when combined with Rifapentine.
Rifaximin	The serum concentration of Erlotinib can be decreased when it is combined with Rifaximin.
Rilonacept	The metabolism of Erlotinib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Erlotinib can be decreased when combined with Rilpivirine.
Riluzole	Erlotinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Erlotinib.
Riociguat	The metabolism of Erlotinib can be decreased when combined with Riociguat.
Ripretinib	Erlotinib may decrease the excretion rate of Ripretinib which could result in a higher serum level.

You Might Also Read Vandetanib; Uses,Dosage, Side Effects, Interactions, Pregnancy

Risperidone	The metabolism of Erlotinib can be decreased when combined with Risperidone.
Ritonavir	The metabolism of Erlotinib can be decreased when combined with Ritonavir.
Rivaroxaban	The metabolism of Erlotinib can be decreased when combined with Rivaroxaban.
Rofecoxib	The serum concentration of Erlotinib can be decreased when it is combined with Rofecoxib.
Roflumilast	The serum concentration of Roflumilast can be increased when it is combined with Erlotinib.
Rolapitant	The metabolism of Erlotinib can be decreased when combined with Rolapitant.
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Erlotinib.
Ropeginterferon	The metabolism of Erlotinib can be decreased when combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Ropivacaine.
Rosiglitazone	The metabolism of Erlotinib can be decreased when combined with Rosiglitazone.
Rosoxacin	The metabolism of Erlotinib can be decreased when combined with Rosoxacin.
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Erlotinib.
Rotigotine	The metabolism of Erlotinib can be decreased when combined with Rotigotine.
Roxadustat	The metabolism of Roxadustat can be decreased when combined with Erlotinib.
Roxithromycin	The metabolism of Erlotinib can be decreased when combined with Roxithromycin.
Rucaparib	The metabolism of Erlotinib can be decreased when combined with Rucaparib.
Rufinamide	The serum concentration of Erlotinib can be decreased when it is combined with Rufinamide.
Rupatadine	The metabolism of Erlotinib can be decreased when combined with Rupatadine.
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Erlotinib.
Sacituzumab	The serum concentration of Sacituzumab govitecan can be increased when it is combined with Erlotinib.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Erlotinib.
Salmeterol	The metabolism of Erlotinib can be decreased when combined with Salmeterol.
Salmon calcitonin	The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Erlotinib.
Saquinavir	The metabolism of Erlotinib can be decreased when combined with Saquinavir.
Sarilumab	The serum concentration of Erlotinib can be decreased when it is combined with Sarilumab.
Satralizumab	The serum concentration of Erlotinib can be decreased when it is combined with Satralizumab.
Saxagliptin	The metabolism of Erlotinib can be decreased when combined with Saxagliptin.
Secobarbital	The serum concentration of Erlotinib can be decreased when it is combined with Secobarbital.
Secukinumab	The metabolism of Erlotinib can be increased when combined with Secukinumab.
Selegiline	The metabolism of Erlotinib can be decreased when combined with Selegiline.
Selexipag	The metabolism of Erlotinib can be decreased when combined with Selexipag.
Selpercatinib	The serum concentration of Erlotinib can be increased when it is combined with Selpercatinib.
Selumetinib	The metabolism of Erlotinib can be decreased when combined with Selumetinib.
Sertindole	The metabolism of Erlotinib can be decreased when combined with Sertindole.
Sertraline	The metabolism of Erlotinib can be decreased when combined with Sertraline.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Erlotinib.
Sildenafil	The metabolism of Erlotinib can be decreased when combined with Sildenafil.
Siltuximab	The serum concentration of Erlotinib can be decreased when it is combined with Siltuximab.
Simeprevir	The metabolism of Erlotinib can be decreased when combined with Simeprevir.
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Erlotinib.
Siponimod	The metabolism of Siponimod can be decreased when combined with Erlotinib.
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Erlotinib.
Sitagliptin	The metabolism of Erlotinib can be decreased when combined with Sitagliptin.
Sitaxentan	The metabolism of Erlotinib can be decreased when combined with Sitaxentan.
Sodium	Sodium bicarbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium zirconium	Sodium zirconium cyclosilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sofosbuvir	Erlotinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The metabolism of Erlotinib can be decreased when combined with Solifenacin.
Somapacitan	The metabolism of Erlotinib can be increased when combined with Somapacitan.
Somatostatin	The metabolism of Erlotinib can be decreased when combined with Somatostatin.
Somatotropin	The metabolism of Erlotinib can be increased when combined with Somatotropin.
Somatrem	The metabolism of Erlotinib can be increased when combined with Somatrem.
Somatrogon	The metabolism of Erlotinib can be increased when combined with Somatrogon.
Sonidegib	The metabolism of Sonidegib can be decreased when combined with Erlotinib.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Erlotinib.
Sotalol	The metabolism of Erlotinib can be decreased when combined with Sotalol.
Sotorasib	The serum concentration of Erlotinib can be decreased when it is combined with Sotorasib.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Sparfloxacin.
Spironolactone	The metabolism of Erlotinib can be decreased when combined with Spironolactone.
St. John’s Wort	The metabolism of Erlotinib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Erlotinib can be decreased when combined with Stiripentol.
Sulfadiazine	The metabolism of Erlotinib can be decreased when combined with Sulfadiazine.
Sulfamethoxazole	The metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole.
Sulfaphenazole	The metabolism of Erlotinib can be decreased when combined with Sulfaphenazole.
Sulfasalazine	Erlotinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.
Sulfinpyrazone	The serum concentration of Erlotinib can be decreased when it is combined with Sulfinpyrazone.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Erlotinib.
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Erlotinib.
Sultopride	The risk or severity of QTc prolongation can be increased when Sultopride is combined with Erlotinib.
Sumatriptan	Erlotinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Erlotinib.
Suvorexant	The metabolism of Erlotinib can be decreased when combined with Suvorexant.
Tacrine	The metabolism of Erlotinib can be decreased when combined with Tacrine.
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Erlotinib.
Tadalafil	The metabolism of Erlotinib can be decreased when combined with Tadalafil.
Tafenoquine	The metabolism of Erlotinib can be decreased when combined with Tafenoquine.
Talazoparib	Erlotinib may decrease the excretion rate of Talazoparib which could result in a higher serum level.
Tamoxifen	The serum concentration of Erlotinib can be decreased when it is combined with Tamoxifen.
Tamsulosin	The metabolism of Erlotinib can be decreased when combined with Tamsulosin.
Tasimelteon	The metabolism of Erlotinib can be decreased when combined with Tasimelteon.
Tazarotene	The metabolism of Erlotinib can be decreased when combined with Tazarotene.
Tazemetostat	The metabolism of Erlotinib can be decreased when combined with Tazemetostat.
Tecovirimat	The serum concentration of Erlotinib can be decreased when it is combined with Tecovirimat.
Tegafur	The metabolism of Tegafur can be decreased when combined with Erlotinib.
Tegaserod	The metabolism of Erlotinib can be decreased when combined with Tegaserod.
Telaprevir	The metabolism of Erlotinib can be decreased when combined with Telaprevir.
Telavancin	The risk or severity of QTc prolongation can be increased when Telavancin is combined with Erlotinib.
Telithromycin	The metabolism of Erlotinib can be decreased when combined with Telithromycin.
Telotristat ethyl	The serum concentration of Erlotinib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Erlotinib.
Teniposide	The metabolism of Erlotinib can be decreased when combined with Teniposide.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erlotinib.
Terbinafine	The serum concentration of Erlotinib can be decreased when it is combined with Terbinafine.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erlotinib.
Terfenadine	The metabolism of Erlotinib can be decreased when combined with Terfenadine.
Teriflunomide	The serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide.
Teriparatide	The therapeutic efficacy of Teriparatide can be decreased when used in combination with Erlotinib.
Terlipressin	The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Erlotinib.
Testosterone	The serum concentration of Erlotinib can be decreased when it is combined with Testosterone.

Tetrabenazine	The metabolism of Erlotinib can be decreased when combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Tetracaine.
Tetracycline	The metabolism of Erlotinib can be decreased when combined with Tetracycline.
Tezacaftor	The metabolism of Erlotinib can be decreased when combined with Tezacaftor.
Thalidomide	The metabolism of Erlotinib can be increased when combined with Thalidomide.
Theophylline	The metabolism of Theophylline can be decreased when combined with Erlotinib.
Thiabendazole	The metabolism of Erlotinib can be decreased when combined with Thiabendazole.
Thiamylal	The metabolism of Erlotinib can be increased when combined with Thiamylal.
Thiopental	The serum concentration of Erlotinib can be decreased when it is combined with Thiopental.
Thioridazine	The metabolism of Erlotinib can be decreased when combined with Thioridazine.
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Erlotinib.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Erlotinib.
Thyroid, porcine	The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Erlotinib.
Thyrotropin alfa	The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Erlotinib.
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Erlotinib.
Ticagrelor	The metabolism of Erlotinib can be decreased when combined with Ticagrelor.
Ticlopidine	The metabolism of Erlotinib can be decreased when combined with Ticlopidine.
Timolol	The metabolism of Erlotinib can be decreased when combined with Timolol.
Tiotropium	The metabolism of Erlotinib can be decreased when combined with Tiotropium.
Tipranavir	The metabolism of Erlotinib can be decreased when combined with Tipranavir.
Tizanidine	The metabolism of Tizanidine can be decreased when combined with Erlotinib.
Tocainide	The metabolism of Erlotinib can be decreased when combined with Tocainide.
Tocilizumab	The serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Erlotinib.
Tolbutamide	The metabolism of Erlotinib can be decreased when combined with Tolbutamide.
Tolterodine	The metabolism of Erlotinib can be decreased when combined with Tolterodine.
Tolvaptan	The metabolism of Tolvaptan can be decreased when combined with Erlotinib.
Topiramate	The metabolism of Erlotinib can be increased when combined with Topiramate.
Topotecan	Erlotinib may decrease the excretion rate of Topotecan which could result in a higher serum level.
Torasemide	The metabolism of Erlotinib can be decreased when combined with Torasemide.
Toremifene	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Toremifene.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Erlotinib.
Tramadol	The metabolism of Tramadol can be decreased when combined with Erlotinib.
Trametinib	The serum concentration of Erlotinib can be decreased when it is combined with Trametinib.
Tranylcypromine	The metabolism of Erlotinib can be decreased when combined with Tranylcypromine.
Trastuzumab	The metabolism of Trastuzumab emtansine can be decreased when combined with Erlotinib.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Erlotinib.
Treprostinil	The serum concentration of Treprostinil can be increased when it is combined with Erlotinib.
Tretinoin	The metabolism of Erlotinib can be decreased when combined with Tretinoin.
Triamcinolone	The serum concentration of Erlotinib can be decreased when it is combined with Triamcinolone.
Triamterene	The metabolism of Erlotinib can be decreased when combined with Triamterene.
Triazolam	The metabolism of Erlotinib can be decreased when combined with Triazolam.
Triclabendazole	The metabolism of Erlotinib can be decreased when combined with Triclabendazole.
Trifluoperazine	The metabolism of Trifluoperazine can be decreased when combined with Erlotinib.
Trilaciclib	The metabolism of Erlotinib can be increased when combined with Trilaciclib.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Erlotinib.
Trimethadione	The metabolism of Erlotinib can be decreased when combined with Trimethadione.
Trimethoprim	The metabolism of Erlotinib can be decreased when combined with Trimethoprim.
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Erlotinib.
Tripelennamine	The metabolism of Erlotinib can be decreased when combined with Tripelennamine.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Erlotinib.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erlotinib.
Troglitazone	The serum concentration of Erlotinib can be decreased when it is combined with Troglitazone.
Troleandomycin	The metabolism of Erlotinib can be decreased when combined with Troleandomycin.
Trospium	The metabolism of Erlotinib can be decreased when combined with Trospium.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Trovafloxacin.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Erlotinib.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Erlotinib.
Udenafil	The metabolism of Erlotinib can be decreased when combined with Udenafil.
Umeclidinium	The metabolism of Erlotinib can be decreased when combined with Umeclidinium.
Valbenazine	The metabolism of Erlotinib can be decreased when combined with Valbenazine.
Valproic acid	The metabolism of Erlotinib can be decreased when combined with Valproic acid.
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Erlotinib.
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Erlotinib.
Velpatasvir	The metabolism of Erlotinib can be decreased when combined with Velpatasvir.
Vemurafenib	The serum concentration of Erlotinib can be decreased when it is combined with Vemurafenib.
Venetoclax	The metabolism of Erlotinib can be decreased when combined with Venetoclax.
Venlafaxine	The metabolism of Erlotinib can be decreased when combined with Venlafaxine.
Verapamil	The metabolism of Erlotinib can be decreased when combined with Verapamil.
Vernakalant	The metabolism of Erlotinib can be decreased when combined with Vernakalant.
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Erlotinib.
Vilazodone	The metabolism of Erlotinib can be decreased when combined with Vilazodone.
Viloxazine	The metabolism of Erlotinib can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Erlotinib can be decreased when it is combined with Vinblastine.
Vincristine	The metabolism of Vincristine can be decreased when combined with Erlotinib.
Vindesine	The metabolism of Vindesine can be decreased when combined with Erlotinib.
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Erlotinib.
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Erlotinib.
Vitamin E	The serum concentration of Erlotinib can be decreased when it is combined with Vitamin E.
Vonoprazan	Vonoprazan can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Vorapaxar	The metabolism of Erlotinib can be decreased when combined with Vorapaxar.
Voriconazole	The metabolism of Erlotinib can be decreased when combined with Voriconazole.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Erlotinib.
Vortioxetine	The metabolism of Erlotinib can be decreased when combined with Vortioxetine.
Voxelotor	The serum concentration of Erlotinib can be increased when it is combined with Voxelotor.
Voxilaprevir	The metabolism of Erlotinib can be decreased when combined with Voxilaprevir.
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Erlotinib.
Yohimbine	The metabolism of Erlotinib can be decreased when combined with Yohimbine.
Zafirlukast	The metabolism of Erlotinib can be decreased when combined with Zafirlukast.
Zaleplon	The metabolism of Erlotinib can be decreased when combined with Zaleplon.
Zanubrutinib	The metabolism of Zanubrutinib can be decreased when combined with Erlotinib.
Zidovudine	The metabolism of Erlotinib can be decreased when combined with Zidovudine.
Zileuton	The metabolism of Erlotinib can be decreased when combined with Zileuton.
Zimelidine	The metabolism of Erlotinib can be decreased when combined with Zimelidine.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ziprasidone.
Zolmitriptan	The metabolism of Erlotinib can be decreased when combined with Zolmitriptan.
Zolpidem	The metabolism of Erlotinib can be decreased when combined with Zolpidem.
Zonisamide	The metabolism of Erlotinib can be decreased when combined with Zonisamide.

Pregnancy and Lactation

FDA Pregnancy Category D

Pregnancy

Erlotinib can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while being treated with erlotinib. Erlotinib has been shown to cause maternal toxicity with associated embryofetal lethality and abortion in rabbits when given at doses that result in plasma drug concentrations of approximately 3 times those in humans (AUCs at 150 mg daily dose). When given during the period of organogenesis to achieve plasma drug concentrations approximately equal to those in humans, based on AUC, there was no increased incidence of embryofetal lethality or abortion in rabbits or rats.

Lactation

No information is available on the clinical use of erlotinib during breastfeeding. Because erlotinib is 93% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 36 hours and it might accumulate in the infant. It is also given in combination with gemcitabine for pancreatic cancer, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 2 weeks after the final dose.

How should this medicine be used?

Erlotinib comes as a tablet to take by mouth. It is usually taken on an empty stomach once a day, at least 1 hour before or 2 hours after eating a meal or snack. Take erlotinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take erlotinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may decrease your dose of erlotinib during your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take erlotinib even if you feel well. Do not stop taking erlotinib without talking to your doctor.

What special precautions should I follow?

Before taking erlotinib,

tell your doctor and pharmacist if you are allergic to erlotinib, any other medications, or any of the ingredients in erlotinib tablets. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: angiogenesis inhibitors such as bevacizumab (Avastin); anticoagulants (‘blood thinners’) such as warfarin (Coumadin); certain antifungals such as itraconazole (Sporanox), ketoconazole (Nizoral), posaconazole (Noxafil), and voriconazole (Vfend); boceprevir (Victrelis); carbamazepine (Tegretol); ciprofloxacin (Cipro, Proquin XR); clarithromycin (Biaxin); conivaptan (Vaprisol); HIV protease inhibitors such as atazanavir (Reyataz), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Fortovase, Invirase); H₂ blockers such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac); medications for acne such as benzoyl peroxide (in Epiduo, in BenzaClin, in Benzamycin, others); midazolam (Versed): nefazodone; nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); oral steroids such as dexamethasone (Decadron, Dexone), methylprednisolone (Medrol), and prednisone (Deltasone); phenobarbital (Luminal, Solfoton); phenytoin (Dilantin); proton pump inhibitors such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), and rabeprazole (AcipHex); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane); rifapentine; taxane medications for cancer such as docetaxel (Taxotere) and paclitaxel (Abraxane, Taxol); telithromycin (Ketek); teriflunomide (Aubagio); and troleandomycin (TAO) (not available in the U.S.). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with erlotinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
if you are taking antacids, take them several hours before or several hours after you take erlotinib.
tell your doctor what herbal products you are taking, especially St. John’s wort.
tell your doctor if you are being treated or have recently been treated with chemotherapy or radiation therapy (treatment for cancer that uses waves of high-energy particles to kill cancer cells). Also tell your doctor if you have or have ever had lung disease or infection, stomach ulcers, diverticular disease (a condition in which abnormal pouches form in the large intestine and may become inflamed), or liver or kidney disease.
tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are taking erlotinib and for at least 1 month after your final dose. Talk to your doctor about birth control methods that you can use. If you become pregnant, call your doctor immediately. Erlotinib may harm the fetus.
tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with erlotinib and for up to 2 weeks after your final dose.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking erlotinib.
tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.
plan to avoid unnecessary or prolonged exposure to sunlight and to wear a hat, other protective clothing, sunglasses, and sunscreen. Choose a sunscreen that has a sun protection factor (SPF) of at least 15 and contains zinc oxide or titanium dioxide. Exposure to sunlight increases the risk that you will develop a rash during your treatment with erlotinib.
you should know that erlotinib may cause rashes and other skin problems. To protect your skin, use a mild alcohol-free moisturizer, wash your skin with mild soap, and remove cosmetics with a mild cleanser.

References